Cambridge Antibody Technology announced last week the retirement of chief medical officer David Glover from the company and the board after the company’s annual general meeting on Feb. 4. Following Glover’s retirement, Patrick Round, vice president for development at CAT, will join the company’s executive group which has responsibility for the operational management of CAT.
In addition, Diane Mellett, general counsel and company secretary at CAT, will join CAT’s board of directors following the Feb. 4 meeting.
Cambridge, UK-based antibody therapeutics company Domantis announced this week the appointment of Mark Skaletsky as non-executive chairman of the Domantis board of directors. Skaletsky is currently CEO of Trine Pharamaceuticals, a Massachusetts-based drug development company focused on renal, gastrointestinal and metabolic diseases. Skaletsky also serves on the boards of several other companies, including Alkermes and Immunogen. He is a member and former chairman of the board of the Biotechnology Industry Organization, Domantis said.
Jeffrey Allard has become vice president and chief scientific officer of Fujirebio Diagnostics, the Mavern, Pa.-based company said last week. He comes to FDI from Immunicon, where he was vice president of clinical research and development. Allard holds a PhD in biochemistry from Dartmouth College, an MS in immunology from Idaho State University, and a BS in pre-veterinary medicine from the University of New Hampshire.